Les anticorps anti-FVIII et anti-FIX

At this day, the development of inhibitory alloantibodies against FVIII or FIX is the main iatrogenic complication of haemophilia A or B. These antibodies compromise the efficacity of the substitutive therapy. Consequences for the physicians are medical, psychologic, social and economic. The development of autoantibodies against coagulation factors in a subject without coagulopathy is a life-threatening event called acquired haemophilia. The detection of anti-factors antibodies and tools available for their physiopathologic study are on constant evolution. The aim of this review is to summarize the mode of interaction, the risk factors and the detection tools for these antibodies. New tools for fine epitope mapping are also exposed. These new technologies are essential for a better understanding of the physiopathologic mechanisms of such antibodies.